Impact of body mass index on overall survival in patients with metastatic breast cancer

Khalil Saleh, Matthieu Carton, Véronique Dieras, Pierre-Etienne Heudel, Etienne Brain, Véronique D'hondt, Audrey Mailliez, Anne Patsouris, Marie-Ange Mouret-Reynier, Anthony Goncalves, et al.

To cite this version:
Khalil Saleh, Matthieu Carton, Véronique Dieras, Pierre-Etienne Heudel, Etienne Brain, et al.. Impact of body mass index on overall survival in patients with metastatic breast cancer. Breast, 2021, 55, pp.16-24. 10.1016/j.breast.2020.11.014 . hal-03345238

HAL Id: hal-03345238

https://hal.science/hal-03345238
Submitted on 28 Nov 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives| 4.0 International License
Impact of body mass index on overall survival in patients with metastatic breast cancer

Khalil Saleh, Matthieu Carton, Véronique Dieras, Pierre-Etienne Heudel, Etienne Brain, Véronique D'Hondt, Audrey Mailliez, Anne Patsouris, Marie-Ange Mouret-Reynier, Anthony Goncalves, Jean Marc Ferrero, Thierry Petit, George Emile, Lionel Uwer, Marc Debled, Florence Dalenc, Christelle Jouannaud, Sylvain Ladoire, Marianne Leheurteur, Paul Cottu, Lucie Veron, Alexia Savignon, Coralie Courtinard, Mathieu Robain, Suzette Delaloge, Elise Deluche

Article history:
Received 14 July 2020
Received in revised form 21 November 2020
Accepted 23 November 2020
Available online 1 December 2020

Keywords:
Metastatic breast cancer
Overall survival
BMI

Abstract
Background: High Body mass index (BMI) is a risk factor for breast cancer among postmenopausal women and an adverse prognostic factor in early-stage. Little is known about its impact on clinical outcomes in patients with metastatic breast cancer (MBC).
Methods: The National ESME-MBC observational cohort includes all consecutive patients newly diagnosed with MBC between Jan 2008 and Dec 2016 in the 18 French comprehensive cancer centers. Of 22 463 patients in ESME-MBC, 12 999 women had BMI data available at MBC diagnosis. Median BMI was 24.9 kg/m² (range 12.1-66.5); 20% of women were obese and 5% underweight. Obesity was associated with more de novo MBC, while underweight patients had more aggressive cancer features. Median overall survival (OS) of the BMI cohort was 47.4 months (95% CI [46.2-48.5]) (median follow-up: 48.6 months). Underweight was independently associated with a worse OS (median OS 33 months).

Abbreviations: BC, breast cancer; BMI, body mass index; ESME, Epidemio-Strategy-Medical-Economical; HR, hormone receptor; MBC, metastatic breast cancer; PFS, progression free-survival; TNBC, triple negative breast cancer; OS, overall survival.

E-mail address: suzette.delaloge@gustaveroussy.fr (S. Delaloge).

https://doi.org/10.1016/j.breast.2020.11.014
0960-9776/© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background

Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death among women in the world [1,2]. The mutual relationship between body mass index (BMI) and breast cancer (BC) risk and outcomes has been widely evaluated. Overweight or obesity is an independent predictor of BC risk in postmenopausal women, while it is protective before menopause [3–5]. BMI has also been demonstrated as an independent prognostic factor for overall survival (OS) in patients with early breast cancer (EBC) [6] [7–8]. However, recent studies question the association between BMI and survival in EBC in certain BC subtypes [9–11]. Many hypotheses have been formulated and explored to explain these observations. Overweight or obesity may affect treatment dosing [12]. Multiple interactions between obesity-linked inflammation, adipose tissue activation or diet-induced metabolic changes and cancer risk or response to treatment have been described [13–15]. In patients with metastatic breast cancer (MBC), limited data are available regarding the impact of BMI on patients’ outcome [16–21].

We therefore interrogated the UNICANCER Epidemic-Strategy-Medical-Economical (ESME)-MBC multicentre national retrospective prospectively maintained cohort, to assess the role of BMI on MBC survival outcomes. This cohort is an academic initiative launched by UNICANCER Group, the French network of cancer centers, to report exhaustive, high quality and centralised real-life data in MBC patients over the past ten years [22,23]. The primary objective of the present study was to evaluate the prognostic impact of BMI at MBC diagnosis on OS of women with metastatic breast cancer. The other objectives were to assess patient characteristics by BMI category, first-line progression-free survival (PFS), and impact of BMI on OS and PFS among the three major BC subtypes.

2. Materials and methods

2.1. ESME data platform and study population

The UNICANCER ESME-MBC data platform is a real-life retrospective, prospectively maintained database that collects exhaustive data of all consecutive patients, male or female, ≥18 years who have initiated their treatment for a MBC in one of 18 French Comprehensive Cancer Centers (FCCC) since January 1st, 2008. For the present study, we used the cohort recruited between this date and December 31, 2016. Data were collected until the cut-off date (October 13, 2018), death, or date of last contact in the centre, if lost to follow-up. Patients’ demographics, cancer characteristics, pathology, outcomes and treatments were collected. Data were annually updated. The information gathered derived from the integration of data from medical records, multidisciplinary team meeting reports, hospitalization-related data and pharmacy-related data, as previously described [22]. Inclusion criteria for the present study (BMI cohort) were female, ≥18 years, and for whom BMI was available at diagnosis of the metastatic disease. Patients with phylloides tumour, angiosarcoma and non-Hodgkin lymphoma, men and patients with MBC treated before January 2008 were excluded. The database and the data were described previously [22].

Four reported BMI categories were defined at the selection date for ESME (first treatment in FCCC) and according to the World Health Organization’s definition: underweight (BMI < 18.5 kg/m²), normal weight (18.5–24.9 kg/m²), overweight (25.0–29.9 kg/m²) and obese (≥30.0 kg/m²).

3. Objectives

Our primary objective was to evaluate whether BMI classified as 4 classes (underweight, normal weight, overweight and obesity) was an independent prognostic factor of OS in patients with MBC regardless of tumour subtype. Secondary objectives were (1) to evaluate whether BMI was an independent prognostic factor of OS in each BC subtype: hormone receptor-positive (estrogen and/or progesterone receptor positive) (HR) and HER2 negative (HR-/HER2-), HER2 positive (HER2+), HER2 positive (HER2+) and triple negative (HR-/HER2-or TNBC); (2) to assess whether BMI classes correlate with other patients and cancer characteristics and (3) to evaluate the potential impact of BMI on progression-free survival under first-line treatment (PFS1) in the overall study population according to the tumour subtype. All details about BC subtype assessment were previously published [23].

3.1. Ethical approval

The ESME research program was authorized by the French data protection authority (Registration ID 1704113 and authorization N-DE-2013.-117, NCT03275311) and is conducted by R&D UNICancer in accordance with current best practice guidelines [24,25]. The present analysis was approved by an independent ethics committee (Comité De Protection Des Personnes Sud-Est II–2015-79).

3.2. Statistical analysis

For descriptive analyses, the significance of the difference in the variables between different BMI groups was estimated using Chi-square tests or ANOVA tests. The primary endpoint, OS, was defined as the time between the date of diagnosis of metastatic disease and date of death (any cause) or censored to the date of latest contact. PFS1 was defined as the time from the initiation of this first-line treatment as time (months) and the date of first disease progression or death or censored to date of latest news. Disease progression was defined as appearance of new metastatic site, progression of existing metastasis, local or locoregional recurrence of the primary tumour, discontinuation of chemotherapy and/or targeted therapy due to metastatic progression (judged by the reference physician), or death from any cause.

We used the Kaplan–Meier method to estimate OS and PFS1, and log-rank tests to assess differences between BMI-subgroups. We used multivariable Cox proportional hazards models to identify prognostic factors of OS and PFS in the whole cohort, and to
calculate Hazard ratios (HR) and associated 95% confidence intervals (CI).

Variables of interest were: BMI at MBC diagnosis, classified as 4 classes (underweight, normal weight, overweight and obesity); age at diagnosis of MBC (≤or ≥65 years); performance status (PS) (PS: 0, 1, 2–4); time to MBC, defined as the time from diagnosis of the primary cancer and diagnosis of MBC (<6 [6–24], 24 months); metastatic sites (bone only, bone and non-visceral metastases [skin, lymph nodes …], visceral metastases [liver, brain metastases] and others); number of metastatic sites (<3, ≥3); MBC subtypes (HR+/HER2-, HER2+ and HR-/HER2-); symptom-versus screening-based diagnosis of MBC (defined as MBC diagnosed on symptoms versus MBC discovered based on the results of a blood or imaging test). All significant factors at 15% level in univariable analysis were included in multivariable analyses. The final models were considered to be reached when including only significant factors at a p = 0.05 significance level. All analyses were performed using R software, version 3.6.1.

4. Results

4.1. Characteristics and treatments of the overall population and BMI-subgroups

Among the 22,463 patients in the ESME-MBC cohort, 12,999 women had available baseline BMI data and constitute the whole BMI cohort (study population) (Fig. 1). Table 1 summarizes this patients and tumors’ characteristics, as well as treatments, by BMI categories. The median age at initial cancer diagnosis and at MBC diagnosis was respectively 53 (range 16–103) and 60 years (range 19–103). The median time to MBC was 27.8 months (range 0.9–94.8 months). Median BMI at MBC was 24.9 kg/m² (range 12.1–66.5 kg/m²). Six hundred thirty-seven patients (5%) were underweight; 6020 (46%) had normal weight; 3708 (29%) were overweight and 2634 (20%) were obese. As shown in Table 1, higher BMI categories were independently and inversely associated with symptom-based MBC diagnosis and positively associated with menopausal status, older age and more de novo MBC (all p < 0.001). Low BMI was associated with the presence of visceral metastases and a higher number of metastatic sites. Conversely, the frequency of bone-only metastases increased with increasing BMI (p < 0.001).

Similarly, the prevalence of HR+ HER2-subtype increased, while the frequency of TNBC subtype decreased with higher BMI.

4.2. Multivariable analysis for OS

The median follow-up of the whole BMI cohort was 48.6 months (range 0–126.1 months). The median OS of the cohort was 47.4 months (95% CI, 46.2–48.5) (Fig. 2A, Supplementary Table A.1). As shown in Fig. 2B, median OS was 33 months (95% CI, 29–40) in the underweight group, 47 months (95% CI, 45–49) in the normal weight group, 49 months (95% CI, 47–51) in the overweight group and 48 months in the obese group (95% CI, 45–51).

In the multivariable analysis, underweight (HR 1.14, 95% CI, 1.02–1.28) was an independent negative predictor for OS, together with PS 2–4 (HR, 3.01; 95% CI, 2.77–3.27), TNBC subtype (HR, 2.18; 95% CI, 2.02–2.36), age at MBC diagnosis ≥65 years (HR, 1.18; 95% CI, 1.12–1.25), presence of visceral metastases (HR, 1.90; 95% CI, 1.76–2.06), time to MBC 6–24 months (HR: 2.53; 95% CI, 2.34–2.74), and the number of metastatic sites ≥3 (HR, 1.45; 95% CI, 1.36–1.54) (Table 2). However, overweight or obesity had no impact on OS.

4.3. Multivariable analysis for first-line PFS

The median PFS1 of the whole cohort was 12.2 months (95% CI, 11.9–12.5). Underweight was associated with a significantly lower median PFS1 (9.2 months; 95% CI, 8.5–10.6) in comparison with the other 3 classes (normal weight: 12.2 (95%CI, 11.8–12.6), overweight: 12.7 (95%CI, 12.1–13.4) and obese: 12.4 (95%CI: 11.6–13.1) (Fig. 2C).

Multivariable analysis showed that underweight (HR, 1.11; 95% CI, 1.01–1.22), the presence of visceral metastases (HR, 1.39; 95% CI, 1.31–1.47), metastatic sites ≥3 (HR, 1.28; 95% CI, 1.22–1.35), PS 2–4 (HR, 1.86; 95% CI, 1.74–1.99) and TNBC subtype (HR, 1.59; 95% CI, 1.5–1.69), were independent predictors of PFS1 (Supplementary Table A.2).

4.4. Multivariable analysis of OS among BC subtypes

When tested among each subtype, underweight was no longer an independent predictor of OS, although it tended to be so among...
patients with TNBC (HR 1.24 [95% CI, 0.99–1.6]). Among TNBC patients, overweight however appeared slightly protective (HR 0.86 [95% CI, 0.75–0.98], p = 0.01). (Supplementary Tables A.3–A5).

Comparison of the study cohort’s characteristics (N = 12 999) with those of patients with no BMI available (N = 9267). Patients included in the present study (based on available BMI data) were diagnosed more recently (50.3% versus 32.2% diagnosed during years 2013–2016), were slightly younger (median age 60 years versus 62 years) and presented more frequently de novo MBC (36.2% vs 21.1%) as compared to women with no BMI available (Supplementary Tables A.6). Patients in the BMI cohort had better OS ([47.4 months [46.2–48.5] vs 31.5 [30.6–32.3]) and PFS1 (12.2 months [11.9–12.5] vs 9.3 months [9.0–9.7]) than those excluded.

5. Discussion

With more than 12 000 patients involved, the present study is the largest assessment yet conducted regarding the impact of BMI on survival outcomes among patients with metastatic breast cancer.

Underweight appears as an independent negative prognostic factor of both OS and first line PFS, while, in contrast, overweight

| Table 1 Patients, tumors characteristics at MBC diagnoses and treatments. |
|----------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Median age at MBC (years)       | Underweight (n = 637) | Normal weight (n = 620) | Overweight (n = 3708) | Obesity (n = 2634) | P               |
| (Q1–Q3 range)                   |                  |                  |                  |                  |                 |
| Age at MBC, n (%)               | 58 (47–68)       | 58 (48–68.2)    | 61 (51–70)       | 60 (52–69)       | <0.001          |
| <65 years                       | 422 (66)         | 3962 (66)       | 2232 (60)        | 1680 (64)        | <0.001          |
| ≥65 years                       | 215 (34)         | 2058 (34)       | 1476 (40)        | 954 (36)         |                 |
| Median BMI (kg/m²)              | 17.5 (16.7–18)   | 22.2 (20.8–23.6) | 27.1 (26.0–28.3) | 33.3 (31.2–36.4) |                 |
| (Q1–Q3 range)                   |                  |                  |                  |                  |                 |
| Menopausal status at MBC, n (%) | 123 (19)         | 1223 (20)       | 563 (15)         | 398 (15)         | <0.001          |
| Premenopausal                   | 267 (42)         | 2694 (45)       | 1843 (50)        | 1386 (53)        |                 |
| Post-menopausal                 | 247 (39)         | 2103 (35)       | 1302 (35)        | 850 (32)         |                 |
| Missing data                    | Time to MBC (median, months) (Q1–Q3 range) | 24.3 (0.7–81.4) | 33 (1.1–103.5) | 27.3 (0.8–92.1) | 18.4 (0.7–77.2) | <0.001          |
| Type of MBC, n (%)              | 228 (35.8)       | 1939 (32.2)     | 1389 (37.5)      | 1132 (42.9)      | <0.001          |
| De novo                         | 406 (63.7)       | 4064 (67.5)     | 2311 (62.3)      | 1496 (56.8)      |                 |
| Recurrent                       | 3 (0.5)          | 17 (0.3)        | 8 (0.2)          | 6 (0.3)          |                 |
| Missing data                    | Mode of MBC diagnosis n (%) (Q1–Q3 range) | 355 (55.7)        | 3366 (55.9)      | 2125 (57.3)      | 1593 (60.5)      | <0.001          |
| Systematic                      | 272 (42.7)       | 2529 (42)       | 1507 (40.6)      | 1012 (38.4)      |                 |
| Symptomatic                     | 10 (1.6)         | 125 (2.1)       | 76 (2)           | 29 (1.1)         |                 |
| Missing data                    | Breast cancer histological type n (%) (Q1–Q3 range) | 468 (73.5)        | 4454 (74.0)      | 2740 (73.9)      | 2043 (77.6)      | 0.012           |
| Infiltrating ductal carcinoma   | 81 (12.7)        | 765 (12.7)      | 462 (12.5)       | 272 (10.3)       |                 |
| Infiltrating lobular carcinoma  | 70 (11.0)        | 682 (11.3)      | 447 (12.1)       | 276 (10.5)       |                 |
| Other                           | 18 (2.8)         | 119 (2.0)       | 59 (1.6)         | 43 (1.6)         |                 |
| Missing data                    | Breast cancer subtype, n (%) (Q1–Q3 range) | 354 (56)          | 3566 (59)        | 2311 (62)        | 1633 (62)        | 0.001           |
| HR = HER2-HER2+                 | 131 (21)         | 1295 (22)       | 725 (20)         | 545 (21)         |                 |
| TNBC                            | 105 (16)         | 860 (14)        | 499 (13)         | 345 (13)         |                 |
| Underdetermined                 | 47 (7)           | 299 (5)         | 173 (5)          | 111 (4)          |                 |
| Metastatic sites, n (%)         | 130 (20)         | 1372 (23)       | 897 (24)         | 688 (26)         | <0.001          |
| Bone only                       | 107 (17)         | 1105 (18)       | 663 (18)         | 462 (18)         |                 |
| Bone and non-visceral metastases| 236 (37)         | 2060 (34)       | 1102 (30)        | 716 (27)         |                 |
| Visceral-only metastases        | 164 (26)         | 1483 (23)       | 1046 (28)        | 768 (29)         |                 |
| Others                          | Presence of visceral metastasis, n (%) (Q1–Q3 range) | 400 (63)          | 3543 (59)        | 2148 (58)        | 1484 (56)        | 0.015           |
| Yes                             | 237 (37)         | 2477 (41)       | 1560 (42)        | 1150 (44)        |                 |
| No                              | 457 (72)         | 4684 (78)       | 2955 (80)        | 2081 (79)        | <0.001          |
| No of metastatic sites, n (%)   | 180 (28)         | 1336 (22)       | 753 (20)         | 553 (21)         |                 |
| ≥3                              | 416 (65)         | 4112 (68)       | 2460 (66)        | 1741 (66)        | 0.07            |
| Yes                             | 221 (35)         | 1908 (32)       | 1248 (34)        | 893 (34)         |                 |
| No                              | 279 (46)         | 1791 (48)       | 1235 (47)        | 1399 (53)        | 0.003           |
| No of targeted therapy during 1st line, n (%) (Q1–Q3 range) | 197 (31)         | 2073 (34)       | 1172 (32)        | 762 (29)         | <0.001          |
| Yes                             | 440 (69)         | 3947 (66)       | 2536 (68)        | 1872 (71)        |                 |

CT: chemotherapy; ET: endocrine therapy, HER2: Human Epidermal Growth Factor Receptor-2; HR: hormone receptor; MBC: metastatic breast cancer; PS: performance status; TNBC: triple-negative breast cancer.

* Type of MBC: MBC is considered ‘de novo’ if the metastatic condition was detected at the same time as the primary cancer or within the following 6 months.
Fig. 2. Overall survival in the whole study population and by BMI classes; First-line progression free survival by BMI classes. Fig. 2a Overall survival of the whole study cohort. Fig. 2b Overall survival in the 4 BMI classes. Fig. 2c First-line progression free survival by BMI classes.
and obese conditions were clearly not associated with prognosis. These results regarding high BMI among MBC patients are however consistent with those reported by Gennari et al. who evaluated the prognostic impact of BMI on OS and PFS in 489 patients with MBC [18]. These results regarding high BMI among MBC patients are however not standard, with a cut-off at 20 kg/m² compared with women with normal weight (HR = 1.29, 95% CI 1.29–1.53) [19]. Recently, Pizzuti et al. analysed data of 196 women with HER2-negativ metastatic BC, treated with paclitaxel and bevacizumab and showed that BMI had no impact on survival particularly in the luminal subgroup [20]. In contrast to our report, these studies did however not distinguish underweight from normal weight patients. Two previous retrospective studies have reported a negative impact of obesity on outcomes in women with BMI <25 and women with BMI ≥25 (p = 0.387 and p = 0.525, respectively) [19].

In our knowledge, there are limited data about the impact of underweight on the long-term outcomes in MBC. A single previous study reported a better prognosis among 557 MBC women with a BMI <20 kg/m² compared with women with normal weight (HR = 0.52, 95% CI 0.31–0.87, p = 0.013). However, patients were included between 1999 and 2008 and treatment regimens were not considered. Furthermore, the definition of underweight used was not standard, with a cut-off at 20 kg/m² [30]. With a WHO definition-based cut-off at 18.5 kg/m², we showed that underweight was strongly associated with a worse prognosis as compared to other groups.

In the ESME MBC cohort, the availability of the BMI at MBC diagnosis varied mainly over time, and is much more frequently reported in recent years. BMI at primary cancer diagnosis was not available. Only 5% of patients in our cohort were underweight, which is in line with data in localised BC cohorts such as the national CANTO cohort [31]. In our study, underweight women had more visceral metastases and more metastatic sites. These two adverse prognostic factors may be associated with a lower BMI because of a poorer general condition and/or a marker of disease aggressiveness. However, no causal relationship between low BMI and outcomes, in a way or the other, can be clearly evidenced from our study. Of note, underweight’s effect appeared however independent of all other risk factors. Treatments received did not differ between BMI categories.

The strengths of the present study are that it is based on a large, high quality updated nationwide, multicentre cohort of patients with MBC and for whom complete information on characteristics,
One limitation of our study is that the ESME MBC cohort is retrospective, with no systematic data on evolution of weight over time, weight loss before diagnosis nor tolerance and safety data. As well, BMI and performance status are not available at MBC diagnosis in the entire ESME population (9267 patients were excluded for missing BMI). No data regarding body composition are available, although that could be of importance. Indeed, BMI alone cannot estimate the women’s muscle mass and adiposity, therefore precluding direct explanation of our results in the underweight population. A large literature has recently assessed the adverse effect of sarcopenia and under-nutritional states in patients with advanced cancer [32–34]. In women with early BC and MBC, an emerging area of research is focusing on body composition rather than overall body weight [35]. Sarcopenia, or low skeletal muscle mass and strength, emerge as an independent prognostic factor in EBC [32,36] as well as MBC in few studies [37–39]. Caan et al. concluded that patients with sarcopenia had a higher overall mortality in a large cohort of non-MBC (n = 3248) [40]. In MBC resistant to anthracycline and/or taxane treatment, Prado et al. reported that sarcopenia was a significant predictor of toxicity and time to tumour progression in patients treated with capecitabine [39]. The discrepancy between the effect of obesity among women with early and metastatic cancers may be related to the already described “obesity paradox” (high BMI is associated with significantly longer cancer-specific survival in individuals with advanced disease) [41,42]. A small recent prospective study suggested that being overweight could improve OS in patients with metastatic BC receiving chemotherapy (n = 82) [43]. Of note, in ESME, overweight patients with the worse subtype (TNBC) indeed had better OS than normal weight ones (HR 0.86 [95% CI, 0.75–0.98], p = 0.01). Another explanation is that BMI is an imprecise measure of body composition. Body composition parameters might help to explain the obesity paradox because in high BMI population, low muscle mass was associated with higher risk of recurrence, overall and cancer-specific mortality [44,45]. Unfortunately we did not have data on cancer-related cachexia in this cohort (muscle strength ...). The differential pharmacokinetics of targeted agents in overweight/obese or underweight patients could be also one possible underlying explanation for different outcomes [46]. However, this study was not designed to provide this type of information.

6. Conclusion

The present study identifies underweight (5% of this MBC patients’ population) as an adverse independent prognostic factor for OS and first line PFS in patients with metastatic breast cancer. Obesity and overweight did however not predict for survival, except among patients with TNBC, where obesity appeared slightly protective. Because of limitations such as reverse causality and treatment selection bias, it is not possible to conclude that the association showed between underweight and outcome is causal. Underweight conditions should however be the focus of clinical attention at the time of MBC diagnosis. They should be explored, and potentially analysed separately in cohort studies. Targeted interventions could be prompted in this subgroup, including nutritional management and/or exercise intervention. Interventions against sarcopenia and undernutrition should involve dieticians and nutritionists. More specifically for sarcopenia, physiotherapists and fitness counsellors in management of muscle loss would be needed.

Contributors

KS and SD: conception and design. MR, MC and CC: data acquisition, interpretation and statistical analysis. VD, PEH, EB, VD, AM, AP, AMR, AG, JMF, TP, EG, LU, MD, FD, CJ, SL, ML, PC, LV and AS: data acquisition, interpretation. KS, SD, ED, MS: interpretation, writing of the first draft of the manuscript. All authors contributed to the manuscript, critically revised the manuscript, and approved the final version.

BMI: body mass index; HR: hazard ratio; MBC: metastatic breast cancer; CI: confidence interval; HR: hormone receptor; HER2: human epidermal growth factor receptor 2; TNBC: triple negative breast cancer.

Declaration of Competing Interest

V.D reports advisory boards from Roche, Genentech, Lilly, Pfizer, Astra Zeneca, MSD, Daiichi Sankyo and Seattle Genetics.

PE-H reports research funding from Pfizer, Novartis

E.B receive honoraria or consultation fees: AstraZeneca, BMS, Celgene, Clincingen, G1 Therapeutics, Hospira, Janssen, Mylan, OBI Pharma, Pfizer, Puma, Roche, Samsung; Receipt of grants/research supports: Amgen, HalioDX (Qiagen/Ipsogen), TEVA (Cephalon); Travel support: AstraZeneca, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz.

A.G reports travel expenses, accommodation and registration meeting from Astra Zeneca, Roche, Pfizer, Novartis.

P.C reports grants form Pfizer and Novartis, personal fees from Pfizer and Lilly, non-financial support from Pfizer.

S.D. reports institutional fees and non-financial support from Roche/Genentech; grants, institutional fees and nonfinancial support from Pfizer; institutional fees and nonfinancial support from Puma; grants, institutional fees and non-financial support from AstraZeneca; grants, institutional fees and non-financial support from Novartis; institutional fees and non-financial support from Amgen.

E.D reports travel expenses from Pfizer, Novartis and Amgen and boards from Novartis and Pfizer.

The other authors declare that they have no conflict of interest to disclose.

Acknowledgements

We thank all patients who allowed us to build the present ESME real life cohort. We thank the 18 French Comprehensive Cancer Centers for providing the data and each ESME local coordinator for managing the project at the local level. We also thank the ESME Scientific Committee members for their ongoing support. Finally, we thank the funders of the ESME program (Roche, Pfizer, AstraZeneca, MSD, Eisai and Daiichi Sankyo).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.breast.2020.11.014.

18 Participating French Comprehensive Cancer Centers (FCCC): I. Curie, Paris/Saint-Cloud, G. Roussy, Villejuif, I. Cancérologie de l’Ouest, Angers/Nantes, C. F. Baclesse, Caen, ICM Montpellier, C. L. Béard, Lyon, C. G-F Leclerc, Dijon, C. H. Becquerel, Rouen; I. C. Regaud, Toulouse; C. A. Lacassagne, Nice; Institut de Cancérologie de Lorraine, Nancy; C. E. Marquis, Rennes; I. Paoli-Calmettes, Marseille; C. J. Perrin, Clermont Ferrand; I. Bergonié, Bordeaux; C. P. Strauss, Strasbourg; I. J. Godinot, Reims; C. O. Lambret, Lille.

ESME central coordinating staff:

Head of Research and Development: Claire Labreveux. Program director: Mathieu Robain.

Data Management team: Coralie Courtinard, Emilie Nguyen, K. Saleh, M. Carton, V. Dieras et al. The Breast 55 (2021) 16–24...
Olivier Payen, Irwin Piot, Dominique Schwob and Olivier Villacroux.
Operational team: Michaël Chevrot, Daniel Couch, Patricia D’Agostino, Pascale Danglot, Tahar Guesmia, Christine Hamonou, Gaëtane Simon and Julie Tort.
Supporting clinical research associates: Elodie Kupfer and Toi-hi Srid.
Project Associate: Nathalie Bouyer.
Management assistant: Esmeralda Pereira.
Software designers: Matou Diop, Blaise Fulpin, José Paredes and Alexandre Vanni.
ESME local coordinators:
Patrick Arveux, Thomas Bachelor, Delphine Berchery, Etienne Brain, Mathias Breton, Loïc Campion, Emmanuel Chapoulley, Valérie Dejean, Stéphanie Delaine, Anne-Valérie Guizard, Anne Jaffré, Lilian Laborde, Carine Laurent, Marie-Paule Lebisyasy, Agnès Loeb, Muriel Mons, Damien Parent, Geneviève Perrocheau, Marie-Ange Mouret-Reynier, Michel Velten.

Ethics approval and consent to participate
The ESME research program was authorized by the French data protection authority (Registration ID 1704113 and authorization No DE-2013.-117, NCT03275311) and conducted by R&D Unicancer in accordance with current best practice guidelines [24,25]. The present analysis was approved by an independent ethics committee (Comité De Protection Des Personnes Sud-Est II- 2015-79).

Consent for publication
All authors provided consent for publication.

Data availability
The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.

Funding
The ESME MBC database receives financial support from an industrial consortium (Roche, Pfizer, AstraZeneca, MSD, Eisai and Daiichi Sankyo). Data collection, analysis and publication is managed entirely by R&D UNICANCER independently of the industrial consortium.

References
[1] Ferlay J, Colombe M, Sorejomataaram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 2018;68:394–424.
[2] Brat DJ, Morin PJ, Kaelin WG Jr, Albertson DG. A new pathway for liver development from the embryonic gonad. J Hepatol 2014;60:1282–92.
[3] Lehmann B, Calvi LM, Linkhart TA, Habener JF, Gudas LJ. An adipocyte-secreted protein required for macrophage recruitment during fat development. J Biol Chem 2006;281:15310–21.
[4] Wang X, Han X, Zhang Y, Huang Y, Zhou Z, Wang S, et al. A novel adipokine, adiponectin, is a potential marker for the prediction of breast cancer metastasis. Int J Oncol 2010;36:1075–81.
[5] D’Agostino RB, Vasan RS, Pencina MJ, Cobain M, Buring JE, Wilson PWF. Validation of Duke’s predictive model for coronary heart disease. JAMA 2008;299:1312–22.
[6] Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon: International Agency for Research on Cancer; 2013.
[7] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29.
[8] Gatta G, Parkin DM, Ronckers CM, Franceschi S, Franceschi C, Berrino F, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon: International Agency for Research on Cancer; 2013.
[9] Zhong Z, Zhang Y, Li H, Wang Y, Wu J, Zhang X, et al. Adiponectin modulates the expression of transforming growth factor-β1 in breast cancer cells. Breast Cancer Res Treat 2014;148:515–24.
[10] D’Agostino RB, Vasan RS, Pencina MJ, Cobain M, Buring JE, Wilson PWF. Validation of Duke’s predictive model for coronary heart disease. JAMA 2008;299:1312–22.
cancer. J Clin Med 2019;8.

[34] Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Canc 2016;57:58–67.

[35] Rossi F, Valdora F, Bignotti B, Torri L, Succio G, Tagliafico AS. Evaluation of body Computed Tomography-determined sarcopenia in breast cancer patients and clinical outcomes: a systematic review. Cancer Treat Res Commun 2019;21:100154.

[36] Deluche E, Lebon S, Desport JC, Venat-Bouvet L, Usseglio J, Tubiana-Mathieu N. Impact of body composition on outcome in patients with early breast cancer. Support Care Canc 2018;26:861–8.

[37] Shachar SS, Deal AM, Weinberg M, Nyrop KA, Williams GR, Nishijima TF, et al. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Canc Res 2018;24:658–65.

[38] Rier HN, Jager A, Sleijfer S, van Rosmalen J, Kock MCJM, Levin M-D. Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer. Breast Canc Res Treat 2018;168:95–105. https://doi.org/10.1007/s10549-017-4574-0.

[39] Prado CMM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Canc Res 2009;15:2920–6.

[40] Caan BJ, Cespedes Feliciano EM, Prado CM, Alexeeff S, Kroenke CH, Bradshaw P, et al. Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 2018;4:798–804.

[41] Hayes AJ, Larkin J. BMI and outcomes in melanoma: more evidence for the obesity paradox. Lancet Oncol 2018;19:269–70.

[42] Choi Y, Park B, Jeong BC, Seo SI, Jeon SS, Choi HY, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Canc 2013;132:625–34.

[43] Alarfi H, Salamoon M, Kadri M, Alammar M, Haykal MA, Alseoudi A, et al. The impact of baseline body mass index on clinical outcomes in metastatic breast cancer: a prospective study. BMC Res Notes 2017;10:550.

[44] Caan BJ, Feliciano EMC, Kroenke CH. The importance of body composition in explaining the overweight paradox in cancer—counterpoint. Canc Res 2018;78:1906–12.

[45] Caan BJ, Meyerhardt JA, Kroenke CH, Alexeeff S, Xiao J, Weltzien E, et al. Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C-SCANS study). Canc Epidemiol Biomarkers Prev 2017;26:1008–15.

[46] González García J, Gutiérrez Nicolás F, Ramos Díaz R, Nazco Casariego GJ, Viña Romero MM, Llabres Martínez M, et al. Pharmacokinetics of trastuzumab after subcutaneous and intravenous administration in obese patients. Ann Pharmacother 2020;54:775–9.